Minikit de ADN/ARN vírico PureLink™
Minikit de ADN/ARN vírico PureLink™
Citas y referencias (8)
Invitrogen™

Minikit de ADN/ARN vírico PureLink™

El minikit de ARN/ADN vírico PureLink proporciona un método rápido y eficaz para purificar simultáneamente ARN/ADN vírico de líquidos biológicosMás información
Have Questions?
Número de catálogoCantidad
1228005050 preparaciones
Número de catálogo 12280050
Precio (CLP)
359.213
Each
Añadir al carro de la compra
Cantidad:
50 preparaciones
Precio (CLP)
359.213
Each
Añadir al carro de la compra
El minikit de ARN/ADN vírico PureLink proporciona un método rápido y eficaz para purificar simultáneamente ARN/ADN vírico de líquidos biológicos (plasma, suero, líquido cefalorraquídeo) extracelulares frescos o congelados y sobrenadantes de cultivo celular. El kit está específicamente diseñado para aislar ácidos nucleicos virales de alta calidad a partir de diversos virus de ARN y ADN en un plazo de 45 minutos mediante volúmenes de elución baja que permiten un análisis posterior sensible. El ARN/ADN viral purificado está desprovisto de proteínas y endonucleasas, y es adecuado para su uso en aplicaciones posteriores que permiten el genotipado y la detección viral.

El minikit viral PureLink se ha utilizado para purificar el ADNbc vírico a partir de ortopoxvirus, incluidos el virus de la varicela de las vacas, el virus de la variola, el virus de la varicela del mono, el virus de la vaccinia y HERV.

El minikit de ARN/ADN viral PureLink proporciona las siguientes ventajas:
• Purificación rápida y eficaz de ácido nucleico vírico de alta calidad mediante centrifugación con columnas de centrifugación sin contaminación cruzada en las muestras
• Específicamente diseñado para purificar el ADN y el ARN víricos a partir de muestras extracelulares de ≤ 500 µl en un plazo de 45 minutos
• Capacidad para eluir ácidos nucleicos víricos en bajos volúmenes de elución de 10–50 µl para permitir análisis posteriores sensibles

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Tipo de columnaColumna de centrifugación
Volumen de elución10 to 50 μL
Tipo de producto finalViral RNA and DNA
Para utilizar con (aplicación)PCR cuantitativa en tiempo real (qPCR), PCR de transcriptasa inversa (RT-PCR) y Northern Blotting
Compatibilidad de alto rendimientoNo compatible con alto rendimiento (manual)
Cantidad50 preparaciones
Tipo de muestraLíquidos sin células, Líquido cefalorraquídeo, Muestras líquidas (p. ej., suero), Plasma, Suero, Virus, Nasopharyngeal Viral Transfer Medium (NPVTM)
BásculaMini
Condiciones de envíoTemperatura ambiente
Cantidad de material de partida≤500 μL
Tiempo de prueba45 min
Producción5 μg (Binding capacity)
Isolation TechnologyColumna de centrifugación de sílice
Unit SizeEach
Contenido y almacenamiento
El minikit de ADN/ARN vírico PureLink™ contiene suficientes reactivos para 50 reacciones.

Contenido del kit:
• 32 ml de tampón de lisis vírico (L22)
• 15 ml de tampón de lavado 5X (W5)
• 2 × 1,6 ml de proteinasa K (20 mg/ml en tampón de almacenamiento)
• 310 µg de ARN portador liofilizado
• 15,5 ml de agua esterilizada, sin ARNasa
• 50 columnas de centrifugación vírica con tubos de recogida
• 2 × 50 tubos de lavado (2,0 ml)
• 50 tubos de recuperación (1,5 ml)

Almacene todos los componentes excepto el ARN portador a temperatura ambiente. El ARN portador debe almacenarse a −20 °C.

Preguntas frecuentes

Are additional wash tubes available for the PureLink Viral RNA/DNA kits if I do not want to use the wash columns twice?

Yes, the Cat. No. for 100 wash tubes is 12282-100.

What is the stability of the Proteinase K in the PureLink Viral RNA/DNA kits?

The Proteinase K solution is stable for 1 year when stored at room temperature. For long-term storage (>1 year) or if room temperature is >25 degrees C, store the Proteinase K solution at 4 degrees C.

What is the difference between serum and plasma?

Plasma is the liquid portion of the blood that is separated from the blood cells by centrifugation. One of the characteristics of plasma is that it clots easily, which is important for hemophiliacs needing a transfusion but is a nuisance in most other applications. By agitating the plasma, one can precipitate the clotting factors as a large clot, and the leftover fluid is called serum. In other words, serum plus clotting factors is plasma, and clotted plasma yields serum.

What is the stability of the carrier RNA in the PureLink Viral RNA/DNA kit, both lyophilized and in solution?

The tRNA is stable for over one year. There was no significant difference in qRT-PCR results with tRNA stored for 10 days at ‘20 degrees C or 42 degrees C. The lyophilized tRNA is stable at ‘20 degrees C, room temperature, 37 degrees C, and 45 degrees C for up to 1 month.

Do I need to use the carrier RNA in the PureLink Viral RNA/DNA kit?

The carrier RNA is tRNA and it may not be necessary. We have tested without the tRNA and obtained excellent results. The tRNA provides a substrate for RNases in the sample to protect the viral RNA until the virus is lysed. You may want to scale down the amount of carrier RNA or leave it out. However, you should validate it in your application to make sure you get the same results as when you include it.

Citations & References (8)

Citations & References
Abstract
Surveillance of feral cats for influenza A virus in north central Florida.
Authors:Gordy JT,Jones CA,Rue J,Crawford PC,Levy JK,Stallknecht DE,Tripp RA,Tompkins SM
Journal:Influenza and other respiratory viruses
PubMed ID:22212818
Please cite this paper as: Gordy JT et al. (2012) Surveillance of feral cats for influenza A virus in North Central Florida. Influenza and Other Respiratory Viruses 6(5), 341–347. Background  Transmission of highly pathogenic avian influenza and the recent pandemic H1N1 viruses to domestic cats and other felids creates concern because ... More
Widespread Virus Replication in Alveoli Drives Acute Respiratory Distress Syndrome in Aerosolized H5N1 Influenza Infection of Macaques.
Authors:Wonderlich ER,Swan ZD,Bissel SJ,Hartman AL,Carney JP,O'Malley KJ,Obadan AO,Santos J,Walker R,Sturgeon TJ,Frye LJ Jr,Maiello P,Scanga CA,Bowling JD,Bouwer AL,Duangkhae PA,Wiley CA,Flynn JL,Wang J,Cole KS,Perez DR,Reed DS,Barratt-Boyes SM
Journal:Journal of immunology (Baltimore, Md. : 1950)
PubMed ID:28062701
Human infections with highly pathogenic avian influenza A (H5N1) virus are frequently fatal but the mechanisms of disease remain ill-defined. H5N1 infection is associated with intense production of proinflammatory cytokines, but whether this cytokine storm is the main cause of fatality or is a consequence of extensive virus replication that ... More
Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors.
Authors:Kutner RH, Zhang XY, Reiser J,
Journal:Nat Protoc
PubMed ID:19300443
'Over the past decade, lentiviral vectors have emerged as powerful tools for transgene delivery. The use of lentiviral vectors has become commonplace and applications in the fields of neuroscience, hematology, developmental biology, stem cell biology and transgenesis are rapidly emerging. Also, lentiviral vectors are at present being explored in the ... More
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan.
Authors:Furuta RA, Miyazawa T, Sugiyama T, Kuratsune H, Ikeda Y, Sato E, Misawa N, Nakatomi Y, Sakuma R, Yasui K, Yamaguti K, Hirayama F
Journal:Retrovirology
PubMed ID:21414229
The involvement of xenotropic murine leukemia virus-related virus (XMRV) in prostate cancer (PC) and chronic fatigue syndrome (CFS) is disputed as its reported prevalence ranges from 0% to 25% in PC cases and from 0% to more than 80% in CFS cases. To evaluate the risk of XMRV infection during ... More
The microbial detection array for detection of emerging viruses in clinical samples--a useful panmicrobial diagnostic tool.
Authors:Rosenstierne MW, McLoughlin KS, Olesen ML, Papa A, Gardner SN, Engler O, Plumet S, Mirazimi A, Weidmann M, Niedrig M, Fomsgaard A, Erlandsson L
Journal:
PubMed ID:24963710
Emerging viruses are usually endemic to tropical and sub-tropical regions of the world, but increased global travel, climate change and changes in lifestyle are believed to contribute to the spread of these viruses into new regions. Many of these viruses cause similar disease symptoms as other emerging viruses or common ... More
View all Minikit de ADN/ARN vírico PureLink™ citations